Select Page

South Delhi Pharma, New Delhi, India

SYLVANT (siltuximab) for Injection, for Intravenous infusion.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

SYLVANT is a prescription medicine. SYLVANT used for multicentric Castleman’s disease (MCD).
INDICATIONS AND USAGE
SYLVANT is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
DOSAGE FORMS & STRENGTHS
• 100 mg of lyophilized powder in a single-use vial. (3)
• 400 mg of lyophilized powder in a single-use vial.
Manufactured By: Janssen Biotech, Inc.
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “SYLVANT (siltuximab) for Injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, and Castleman's disease, among other types of cancer.

On April 23, 2014, siltuximab was FDA approved under the brand name of Sylvant for the treatment of patients with idiopathic multicentric Castleman’s disease (iMCD) who do not have human immunodeficiency virus (HIV) or human herpesvirus-8 (HHV-8).

7 reviews for SYLVANT (siltuximab) for Injection, for Intravenous infusion.

There are no reviews yet.

Be the first to review “SYLVANT (siltuximab) for Injection, for Intravenous infusion.”

Your email address will not be published.